This $329,304 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will fund a research project titled "EARLY AND PERSONALIZED CARDIOVASCULAR DISEASE PREVENTIVE CARE IN LUPUS NEPHRITIS (EPIC-LN)". The goal is to develop effective atherosclerotic cardiovascular disease (ASCVD) preventive interventions that support clinicians and patients in decision-making and promote use of ASCVD-risk reducing therapies to improve outcomes and survival in lupus nephritis (LN) patients, especially those of Black race who face higher ASCVD risk. The project aims to: 1) Develop an implementation guide for clinicians to tailor ASCVD prevention and start risk-reducing therapies based on evidence; 2) Create a shared decision-making tool for patients and clinicians; and 3) Test the guide and tool in clinics to evaluate adoption, use, and real-world impact. This research provides a foundation for future multi-site studies to assess the effectiveness of ASCVD preventive interventions in reducing risk for LN patients.
Generated 3/4/25, 2:54 AM